ORAL DRUG TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES MELITO

Detalhes bibliográficos
Autor(a) principal: Pinho Silveiro, Sandra
Data de Publicação: 2022
Outros Autores: Leitão, Cristiane, Coester, Ariane, Gross, Jorge Luiz
Tipo de documento: Artigo
Idioma: por
Título da fonte: Clinical and Biomedical Research
Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/126202
Resumo: Diet, exercise and weight reduction are the cornerstone of type 2 diabetes mellitus (DM) treatment, since most of these patients are obese. However, the majority of the individuals is not able to achieve and mantain a satisfactory glycemic control employing only these strategies, and the prescription of complementary pharmacological treatment is often necessary. The available oral agents for type 2 diabetes treatment are divided in 5 main classes: sulfonylureas, biguanides, thiazolidinediones, alfa-glucosidase inhibitors and glinides. Phase II studies are presently in course, evaluating the safety and efficacy of new drugs. Metformin belongs to biguanides’ class, and is the drug with the best profile, since not only it lowers glycemia, but it also reduces appetite and weight, and , most of all, it is the only drug that diminishes mortality rates. Data regarding indications, mechanisms of action and adverse effects of the above mentioned drugs are describe in the present review.
id UFRGS-20_ed9b75f562b6de086578d3d4162dec59
oai_identifier_str oai:seer.ufrgs.br:article/126202
network_acronym_str UFRGS-20
network_name_str Clinical and Biomedical Research
repository_id_str
spelling ORAL DRUG TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES MELITOTRATAMENTO MEDICAMENTOSO ORAL DA HIPERGLICEMIA NO DIABETE MELITO TIPO 2Tratamento DM 2hipoglicemiantes oraiscontrole glicêmicotype 2 DM treatmentoral hypoglycemic agentsglycemic controlDiet, exercise and weight reduction are the cornerstone of type 2 diabetes mellitus (DM) treatment, since most of these patients are obese. However, the majority of the individuals is not able to achieve and mantain a satisfactory glycemic control employing only these strategies, and the prescription of complementary pharmacological treatment is often necessary. The available oral agents for type 2 diabetes treatment are divided in 5 main classes: sulfonylureas, biguanides, thiazolidinediones, alfa-glucosidase inhibitors and glinides. Phase II studies are presently in course, evaluating the safety and efficacy of new drugs. Metformin belongs to biguanides’ class, and is the drug with the best profile, since not only it lowers glycemia, but it also reduces appetite and weight, and , most of all, it is the only drug that diminishes mortality rates. Data regarding indications, mechanisms of action and adverse effects of the above mentioned drugs are describe in the present review.Dieta, exercício e redução de peso são a base do tratamento do diabete melito (DM) tipo 2, uma vez que a maioria desses pacientes são obesos. No entanto, a maior parte dos indivíduos não consegue atingir e manter um controle glicêmico adequado apenas com estas medidas, sendo freqüentemente necessária a prescrição de tratamento farmacológico complementar. As drogas orais para o tratamento do DM tipo 2 são divididas em 5 classes principais: as sulfoniluréias, as biguanidas, as tiazolidinedionas, os inibidores da alfa-glicosidase e as glinidas. Estudos de fase II estão atualmente em curso, avaliando a eficácia e a segurançade novas drogas. A Metformina, representante das biguanidas, é a droga com o melhor perfil de ação, uma vez que além de controlar a glicemia, também diminui o apetite, causa diminuição do peso (ou evita seu aumento) e, sobretudo, é a única droga que promove redução de  mortalidade. Dados principais sobre as indicações, mecanismos de ação e efeitos colaterais das drogas mencionadas estão descritos por categoria nesta revisão.HCPA/FAMED/UFRGS2022-09-23info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed Article"A Convite dos Editoresapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/126202Clinical & Biomedical Research; Vol. 23 No. 1 - 2 (2003): Revista HCPAClinical and Biomedical Research; v. 23 n. 1 - 2 (2003): Revista HCPA2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSporhttps://seer.ufrgs.br/index.php/hcpa/article/view/126202/85686Copyright (c) 2022 Sandra Pinho Silveiro, Cristiane Leitão, Ariane Coester, Jorge Luiz Grosshttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessPinho Silveiro, Sandra Leitão, Cristiane Coester, Ariane Gross, Jorge Luiz 2022-09-27T20:38:15Zoai:seer.ufrgs.br:article/126202Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2022-09-27T20:38:15Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.none.fl_str_mv ORAL DRUG TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES MELITO
TRATAMENTO MEDICAMENTOSO ORAL DA HIPERGLICEMIA NO DIABETE MELITO TIPO 2
title ORAL DRUG TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES MELITO
spellingShingle ORAL DRUG TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES MELITO
Pinho Silveiro, Sandra
Tratamento DM 2
hipoglicemiantes orais
controle glicêmico
type 2 DM treatment
oral hypoglycemic agents
glycemic control
title_short ORAL DRUG TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES MELITO
title_full ORAL DRUG TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES MELITO
title_fullStr ORAL DRUG TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES MELITO
title_full_unstemmed ORAL DRUG TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES MELITO
title_sort ORAL DRUG TREATMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES MELITO
author Pinho Silveiro, Sandra
author_facet Pinho Silveiro, Sandra
Leitão, Cristiane
Coester, Ariane
Gross, Jorge Luiz
author_role author
author2 Leitão, Cristiane
Coester, Ariane
Gross, Jorge Luiz
author2_role author
author
author
dc.contributor.author.fl_str_mv Pinho Silveiro, Sandra
Leitão, Cristiane
Coester, Ariane
Gross, Jorge Luiz
dc.subject.por.fl_str_mv Tratamento DM 2
hipoglicemiantes orais
controle glicêmico
type 2 DM treatment
oral hypoglycemic agents
glycemic control
topic Tratamento DM 2
hipoglicemiantes orais
controle glicêmico
type 2 DM treatment
oral hypoglycemic agents
glycemic control
description Diet, exercise and weight reduction are the cornerstone of type 2 diabetes mellitus (DM) treatment, since most of these patients are obese. However, the majority of the individuals is not able to achieve and mantain a satisfactory glycemic control employing only these strategies, and the prescription of complementary pharmacological treatment is often necessary. The available oral agents for type 2 diabetes treatment are divided in 5 main classes: sulfonylureas, biguanides, thiazolidinediones, alfa-glucosidase inhibitors and glinides. Phase II studies are presently in course, evaluating the safety and efficacy of new drugs. Metformin belongs to biguanides’ class, and is the drug with the best profile, since not only it lowers glycemia, but it also reduces appetite and weight, and , most of all, it is the only drug that diminishes mortality rates. Data regarding indications, mechanisms of action and adverse effects of the above mentioned drugs are describe in the present review.
publishDate 2022
dc.date.none.fl_str_mv 2022-09-23
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Article"
A Convite dos Editores
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/126202
url https://seer.ufrgs.br/index.php/hcpa/article/view/126202
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/126202/85686
dc.rights.driver.fl_str_mv Copyright (c) 2022 Sandra Pinho Silveiro, Cristiane Leitão, Ariane Coester, Jorge Luiz Gross
http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Sandra Pinho Silveiro, Cristiane Leitão, Ariane Coester, Jorge Luiz Gross
http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv HCPA/FAMED/UFRGS
publisher.none.fl_str_mv HCPA/FAMED/UFRGS
dc.source.none.fl_str_mv Clinical & Biomedical Research; Vol. 23 No. 1 - 2 (2003): Revista HCPA
Clinical and Biomedical Research; v. 23 n. 1 - 2 (2003): Revista HCPA
2357-9730
reponame:Clinical and Biomedical Research
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Clinical and Biomedical Research
collection Clinical and Biomedical Research
repository.name.fl_str_mv Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv ||cbr@hcpa.edu.br
_version_ 1799767057557880832

Registros relacionados